CRDF Stock Summary and Trading Ideas (Cardiff Oncology | NASDAQ:CRDF)

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

What symbol and exchange does Cardiff Oncology shares trade?

Cardiff Oncology trades on the NASDAQ stock market under the symbol CRDF.

What is Cardiff Oncology stock price doing today?

As of January 16, 2026, CRDF stock price climbed to $2.88 with 732,340 million shares trading.

What is Cardiff Oncology's Beta?

CRDF has a beta of 1.26, meaning it tends to be more sensitive to market movements. CRDF has a correlation of 0.06 to the broad based SPY ETF.

How much is Cardiff Oncology worth?

CRDF has a market cap of $191.59 million. This is considered a Micro Cap stock.

How much money does Cardiff Oncology make?

Last quarter Cardiff Oncology reported $120,000 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-12,858 and exceeded earnings estimates by $.03.

What is the highest and lowest price Cardiff Oncology traded in the last 3 year period?

In the last 3 years, CRDF traded as high as $6.42 and as low as $.94.

What are the top ETFs holding Cardiff Oncology?

The top ETF exchange traded funds that CRDF belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

Is Cardiff Oncology (CRDF) a good investment?

CRDF has underperformed the market in the last year with a return of -15.3%, while SPY returned +18.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CRDF shares. However, CRDF has outperformed the market in the last 3 month and 2 week periods, returning +28.6% and +8.3%, while SPY returned +5.0% and +1.2%, respectively. This indicates CRDF has been having a stronger performance recently.

What are the support and resistance levels for Cardiff Oncology (CRDF)?

CRDF support price is $2.65 and resistance is $2.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRDF shares will trade within this expected range on the day.